The efficacy of HDAC inhibitors in combination with tyrosine kinase inhibitor imatinib was previously described for CML cells [55]; however, pan-HDAC inhibitors often exhibit high toxicity in patients. This evidence concerns the gene HDAC9 and chronic myelogenous leukemia, BCR-ABL1 positive.